FibroScan

{0}------------------------------------------------ Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized image of three human profiles facing right, with flowing lines representing hair or clothing. Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 September 1, 2015 Echosens % Zvi Ladin Principal Boston Medtech Advisors Inc. 990 Washington Street, Suite #204 DEDHAM, MA 02026 Re: K150239 Trade/Device Name: FibroScan Regulation Number: 21 CFR 892.1560 Regulation Name: Ultrasonic Pulsed Echo Imaging System Regulatory Class: Class II Product Code: IYO, ITX Dated: July 30, 2015 Received: August 3, 2015 Dear Zvi Ladin: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in {1}------------------------------------------------ the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Sincerely yours, Robert A Ochs Robert Ochs, Ph.D. Director Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ #### DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration ### Indications for Use 510(k) Number (if known) K150239 Device Name FibroScan® Indications for Use (Describe) The FibroScan® system is intended to provide 50Hz shear wave speed measurements and estimates of tissue stiffness through internal structures of the body. FibroScan® is indicated for noninvasive measurement of shear wave speed and estimate of stiffness at 50 Hz in the liver. The shear wave speed may be used as an aid to clinical management of pediatric and adult patients with liver disease. #### Type of Use (Select one or both, as applicable) Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C) PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED. #### FOR FDA USE ONLY Concurrence of Center for Devices and Radiological Health (CDRH) (Signature) This section applies only to requirements of the Paperwork Reduction Act of 1995. # *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* The burden time for this collection of information is estimated to average 79 hours per response, including the The builden time for this collection of intrion data sources, gather and maintain the data needed and complete time to review instruction. Send common regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: > Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." {3}------------------------------------------------ System: FibroScan® 502 Touch | Clinical Application | | Mode of Operation | | | | | | | |-----------------------------|------------------------------------|-------------------|---|-----|-----|------------------|-----------------------|---------------------| | General<br>(Track 1 Only) | Specific<br>(Tracks 1 & 3) | B | M | PWD | CWD | Color<br>Doppler | Combined<br>(Specify) | Other*<br>(Specify) | | Ophthalmic | Ophthalmic | | | | | | | | | Fetal<br>Imaging<br>& Other | Fetal | | | | | | | | | | Abdominal | | P | | | | | P 1, 2 | | | Intra-operative (Specify) | | | | | | | | | | Intra-operative (Neuro) | | | | | | | | | | Laparoscopic | | | | | | | | | | Pediatric | | N | | | | | N 1, 2 | | | Small Organ (Specify) | | | | | | | | | | Neonatal Cephalic | | | | | | | | | | Adult Cephalic | | | | | | | | | | Trans-rectal | | | | | | | | | | Trans-vaginal | | | | | | | | | | Trans-urethral | | | | | | | | | | Trans-esoph. (non-Card.) | | | | | | | | | | Musculo-skeletal<br>(Conventional) | | | | | | | | | | Musculo-skeletal<br>(Superficial) | | | | | | | | | | Intravascular | | | | | | | | | | Other (Specify) | | | | | | | | | Cardiac | Cardiac Adult | | | | | | | | | | Cardiac Pediatric | | | | | | | | | | Intravascular (Cardiac) | | | | | | | | | | Trans-esoph. (Cardiac) | | | | | | | | | | Intra-cardiac | | | | | | | | | | Other (Specify) | | | | | | | | | Peripheral<br>Vessel | Peripheral vessel | | | | | | | | | | Other (Specify) | | | | | | | | Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows: N = new indication; P = previously cleared by FDA; E = added under this appendix 1. A-mode {4}------------------------------------------------ Transducer: FibroScan® M+ probe | | **** ded Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follow. | | | | | |--|-------------------------------------------------------------------------------------------------|--|--|--|--| |--|-------------------------------------------------------------------------------------------------|--|--|--|--| | Clinical Application | | Mode of Operation | | | | | | | | |---------------------------|----------------------------|-------------------|---|-----|-----|------------------|-----------------------|---------------------|--| | General<br>(Track 1 Only) | Specific<br>(Tracks 1 & 3) | B | M | PWD | CWD | Color<br>Doppler | Combined<br>(Specify) | Other*<br>(Specify) | | | Ophthalmic | Ophthalmic | | | | | | | | | | | Fetal | | | | | | | | | | | Abdominal | | P | | | | | P 1, 2 | | | | Intra-operative (Specify) | | | | | | | | | | | Intra-operative (Neuro) | | | | | | | | | | | Laparoscopic | | | | | | | | | | | Pediatric | | N | | | | | N 1,2 | | | Fetal | Small Organ (Specify) | | | | | | | | | | Imaging | Neonatal Cephalic | | | | | | | | | | & Other | Adult Cephalic | | | | | | | | | | | Trans-rectal | | | | | | | | | | | Trans-vaginal | | | | | | | | | | | Trans-urethral | | | | | | | | | | | Trans-esoph. (non-Card.) | | | | | | | | | | | Musculo-skeletal | | | | | | | | | | | (Conventional) | | | | | | | | | | | Musculo-skeletal | | | | | | | | | | | (Superficial) | | | | | | | | | | | Intravascular | | | | | | | | | | | Other (Specify) | | | | | | | | | | | Cardiac Adult | | | | | | | | | | Cardiac | Cardiac Pediatric | | | | | | | | | | | Intravascular (Cardiac) | | | | | | | | | | | Trans-esoph. (Cardiac) | | | | | | | | | | | Intra-cardiac | | | | | | | | | | | Other (Specify) | | | | | | | | | | Peripheral | Peripheral vessel | | | | | | | | | | Vessel | Other (Specify) | | | | | | | | | N = new indication; P = previously cleared by FDA; E = added under this appendix 1. A-mode {5}------------------------------------------------ Transducer: FibroScan® XL+ probe | Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows: | | | | | | | |--------------------------------------------------------------------------------------------------|--|--|--|--|--|--| | | | | | | | | | Clinical Application | | Mode of Operation | | | | | | | |-----------------------------|------------------------------------|-------------------|---|-----|-----|------------------|-----------------------|---------------------| | General<br>(Track 1 Only) | Specific<br>(Tracks 1 & 3) | B | M | PWD | CWD | Color<br>Doppler | Combined<br>(Specify) | Other*<br>(Specify) | | Ophthalmic | Ophthalmic | | | | | | | | | | Fetal | | | | | | | | | Fetal<br>Imaging<br>& Other | Abdominal | | P | | | | | P 1, 2 | | | Intra-operative (Specify) | | | | | | | | | | Intra-operative (Neuro) | | | | | | | | | | Laparoscopic | | | | | | | | | | Pediatric | | | | | | | | | | Small Organ (Specify) | | | | | | | | | | Neonatal Cephalic | | | | | | | | | | Adult Cephalic | | | | | | | | | | Trans-rectal | | | | | | | | | | Trans-vaginal | | | | | | | | | | Trans-urethral | | | | | | | | | | Trans-esoph. (non-Card.) | | | | | | | | | | Musculo-skeletal<br>(Conventional) | | | | | | | | | | Musculo-skeletal<br>(Superficial) | | | | | | | | | | Intravascular | | | | | | | | | | Other (Specify) | | | | | | | | | Cardiac | Cardiac Adult | | | | | | | | | | Cardiac Pediatric | | | | | | | | | | Intravascular (Cardiac) | | | | | | | | | | Trans-esoph. (Cardiac) | | | | | | | | | | Intra-cardiac | | | | | | | | | | Other (Specify) | | | | | | | | | Peripheral<br>Vessel | Peripheral vessel | | | | | | | | | | Other (Specify) | | | | | | | | N = new indication; P = previously cleared by FDA; E = added under this appendix 1. A-mode {6}------------------------------------------------ Transducer: FibroScan® S+ probe | | | | Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows: | | |--|--|--|--------------------------------------------------------------------------------------------------|--| |--|--|--|--------------------------------------------------------------------------------------------------|--| | Clinical Application | | Mode of Operation | | | | | | | |-----------------------------|------------------------------------|-------------------|---|-----|-----|------------------|-----------------------|---------------------| | General<br>(Track 1 Only) | Specific<br>(Tracks 1 & 3) | B | M | PWD | CWD | Color<br>Doppler | Combined<br>(Specify) | Other*<br>(Specify) | | Ophthalmic | Ophthalmic | | | | | | | | | Fetal<br>Imaging<br>& Other | Fetal | | | | | | | | | | Abdominal | | | | | | | | | | Intra-operative (Specify) | | | | | | | | | | Intra-operative (Neuro) | | | | | | | | | | Laparoscopic | | | | | | | | | | Pediatric | | N | | | | | N 1, 2 | | | Small Organ (Specify) | | | | | | | | | | Neonatal Cephalic | | | | | | | | | | Adult Cephalic | | | | | | | | | | Trans-rectal | | | | | | | | | | Trans-vaginal | | | | | | | | | | Trans-urethral | | | | | | | | | | Trans-esoph. (non-Card.) | | | | | | | | | | Musculo-skeletal<br>(Conventional) | | | | | | | | | | Musculo-skeletal<br>(Superficial) | | | | | | | | | | Intravascular | | | | | | | | | | Other (Specify) | | | | | | | | | Cardiac | Cardiac Adult | | | | | | | | | | Cardiac Pediatric | | | | | | | | | | Intravascular (Cardiac) | | | | | | | | | | Trans-esoph. (Cardiac) | | | | | | | | | | Intra-cardiac | | | | | | | | | | Other (Specify) | | | | | | | | | Peripheral<br>Vessel | Peripheral vessel | | | | | | | | | | Other (Specify) | | | | | | | | N = new indication; P = previously cleared by FDA; E = added under this appendix 1. A-mode {7}------------------------------------------------ #### 510(K) Summary Echosens' FibroScan® System #### Submitter's Name, Address, Telephone Number, Contact Persona and Date Prepared: | Manufacturer: | Echosens<br>30 Place d'Italie<br>75013 Paris, France<br>Telephone: +33 1 44 82 78 55<br>Facsimile: +33 1 44 82 68 36 | |-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Contact Person: | Zvi Ladin, Ph.D.<br>Principal<br>Boston MedTech Advisors, Inc.<br>990 Washington Street<br>Suite #204<br>Dedham, MA 02026<br>Telephone: (781) 407 0900 x104<br>Facsimile: (781) 407 0901<br>Email: zladin@bmtadvisors.com | | Date Prepared: | July 30, 2015 | #### Name of Device and Name/Address of Sponsor | Trade/Proprietary Name: | FibroScan® | |-------------------------|------------| |-------------------------|------------| Common Name: Diagnostic Ultrasound System and Accessories Classifications: | Classification Name | Regulation | Product Code | |---------------------------------------|------------------|--------------| | Ultrasonic Pulsed Echo Imaging System | 21 CFR §892.1560 | IYO | | Diagnostic Ultrasonic Transducer | 21 CFR §892.1570 | ITX | | Manufacturing Facility: | Echosens<br>30 Place d'Italie<br>75013 Paris, France<br>Telephone: +33 1 44 82 78 55<br>Facsimile: +33 1 44 82 68 36 | |-------------------------|----------------------------------------------------------------------------------------------------------------------| |-------------------------|----------------------------------------------------------------------------------------------------------------------| | Establishment | | |----------------------|------------| | Registration Number: | 3010258456 | #### Predicate Device This submission claims substantial equivalence to a combination of two cleared devices: 1. FibroScan® (#K123806) manufactured by the sponsor and cleared on April 5, 2013; and 2. Aixplorer® (#K132274) manufactured by Supersonic Imagine S.A. and cleared on September 24, 2013. {8}------------------------------------------------ ### Device Description FibroScan® system consists of a system unit and a hand-held probe. It is based on Vibration-Controlled Transient Elastography (VCTE™) technology, and is designed to perform non-invasive measurements of liver shear wave speed and estimates of tissue stiffness. The probe containing a mechanical vibrator produces low-amplitude elastic waves that travel through the skin and intercostal space into the liver. Ultrasound is used to track the shear (elastic) wave, measure its speed and provide estimated stiffness. The results are displayed on the system unit. The focus of this submission is the expansion of the indications for use for the FibroScan system by Echosens to pediatric patients. In order to address the smaller anatomic size of pediatric patients, a new probe (S+) was developed, and the indications for use of the previously cleared M+ probe were modified. The new probe uses the same principle of operation, intended use and methodology (i.e. application to patient, signal measurement, processing and display), design, materials, manufacturing and testing processes as the previously cleared M+ and XL+ probes. The device specifications are similar to those of the predicate device. The system's software was upgraded to accommodate these changes. ## Recognized Consensus Standards Used Non-clinical testing to assure compliance with acoustic output, biocompatibility as well as thermal, electrical, electromagnetic and mechanical safety were performed and have been found to conform to applicable standards. The system complies with the following standards: - IEC 60601-2-37 Edition 2.0 2007-08:Medical Electrical Equipment Part 2-37: Particular . Requirements For The Basic Safety And Essential Performance Of Ultrasonic Medical Diagnostic And Monitoring Equipment. - NEMA UD 2-2004 (R2009): Acoustic Output Measurement Standard For Diagnostic ● Ultrasound Equipment Revision 3 - AIUM MUS: Medical Ultrasound Safety, Third Edition - . IEC 62127-1 Edition 1.1 2013-02: Ultrasonics -- Hydrophones -- Part 1: Measurement And Characterization Of Medical Ultrasonic Fields Up To 40 Mhz - IEC 62127-2 Edition 1.0 2007-08: Ultrasonics -- Hydrophones -- Part 2: Calibration For . Ultrasonic Fields Up To 40 Mhz [Including: Technical Corrigendum 1:2008 And Amendment 1:2013] - . IEC 62127-03 Edition 1.1 2013-05: Ultrasonics -- Hydrophones -- Part 3: Properties Of Hydrophones For Ultrasonic Fields Up To 40 Mhz - . IEC 61161 Edition 3.0 2013-01: Ultrasonics -- Power Measurement -- Radiation Force Balances And Performance Requirements - . AAMI / ANSI ES60601-1:2005/(R)2012: Medical Electrical Equipment - Part 1: General Requirements For Basic Safety And Essential Performance (IEC 60601-1:2005, Mod) - IEC 60601-1-2 Edition 3:2007-03: Medical Electrical Equipment Part 1-2: General . Requirements For Basic Safety And Essential Performance - Collateral Standard: Electromagnetic Compatibility - Requirements And Tests {9}------------------------------------------------ - . IEC 60601-1-6 Edition 3.1 2013-10: Medical Electrical Equipment - Part 1-6: General Requirements For Basic Safety And Essential Performance - Collateral Standard: Usabilitv - . IEC 62366 Edition 1.1 2014-01: Medical Devices - Application Of Usability Engineering To Medical Devices - . IEC 62304 First Edition 2006-05: Medical Device Software - Software Life Cycle Processes - ISO 14971 Second Edition 2007-03-01: . Medical Devices - Application Of Risk Management To Medical Devices ## Performance Data The bias and precision of the device was documented based on tests performed on phantoms with known elasticity. The bias, i.e. the difference in the mean shear wave speed measured and the nominal shear wave of the phantom, normalized by the nominal shear wave and expressed in percent was evaluated and compared to the corresponding value reported for the predicate devices. While the Aixplorer® predicate device¹ pediatric probes reported values of bias between (-7.2%) and (43.4%), and the FibroScan® predicate devices reported values of bias between (-13.9%) and (1.3%); the range of bias values measured for the candidate device were between (-13.5%) and (3.6%). Therefore, the overall range of bias values (across all values) for the Aixplorer predicate device probes are ~50% of the nominal shear wave speed, while the corresponding range for the predicate FibroScan probes and for the candidate device probe is <20%. Hence, the candidate device has a bias value that is similar or better than that of the predicate device. Similarly, the system's precision, i.e. the standard deviation of the independent measurements of the shear wave speed, normalized by the reference value was calculated. The range of values reported for the Aixplorer® predicate device pediatric probes were between (0%) and (3.4%), and for the FibroScan® predicate device probes were between (0%) and (3.1%), while the corresponding range for the candidate device probe was between (0.7%) and (2%). Therefore, the precision of all systems is similar - range of precision values of ~3% for the predicate device and ~2% for the candidate device. #### Intended Use / Indications for Use FibroScan® is intended to provide 50Hz shear wave speed measurements and estimates of tissue stiffness through internal structures of the body. FibroScan® is indicated for noninvasive measurement of shear wave speed and estimate of stiffness at 50 Hz in the liver. The shear wave speed may be used as an aid to clinical management of pediatric and adult patients with liver disease. #### Comparison of Technological Characteristics ¹ The specific values of precision and bias for the AIXPLORER system are quoted from the 510(k) Summary of #K112255 which is the predicate for #K132274 and is stated to have a substantially equivalent non-clinical performance {10}------------------------------------------------ The new S+ probe and the revised software are substantially equivalent to the predicate device (FibroScan® – #K123806) manufactured by the sponsor and cleared on April 5, 2013. The proposed device uses the same technology, intended use and methodology (i.e. application to patient, signal measurement, processing and display) as the FibroScan system. It is designed to accommodate the anatomy of pediatric patients. The expansion of the Indications for Use of the FibroScan System with the new S* probe to include pediatric patients is substantially equivalent to the diagnostic ultrasound Indications for Use of the ShearWave™ Elastography mode of the Aixplorer (#K132274) for pediatric patients. The candidate device uses the S* ultrasound transducer at a center frequency of 5 MHz, which is in the range of frequencies used by the Aixplorer predicate system for pediatic applications. The analog front end and central interface of the candidate and predicate devices have equivalent functionality. In summary, the candidate and predicate devices are based on the same physical phenomenon. namely the effect of soft tissue elasticity on the propagation of low frequency mechanical waves in internal organs. They use ultrasound for measuring the strain field that results from the propagation of the mechanical wave, and display the shear wave speed and stiffness estimate. Therefore, the candidate and predicate devices are substantially equivalent in terms of the technology used. # Substantial Equivalence Discussion The focus of this submission is the expansion of the indications for use for the FibroScan system by Echosens to pediatric patients. Therefore, substantial equivalence is claimed to the primary predicate device - the original FibroScan System (#K123806) in terms of the intended use, scientific principle, technological design, materials used, patient interface, data collection, processing and display. Substantial equivalence is also claimed to the secondary predicate device (AIXPLORER® #K132274), in terms of the indications for use (elastography for pediatric population), technological characteristics, signal acquisition, processing and display. In order to address the smaller anatomic size of pediatric patients, a new probe (S+) was developed, and the indications for use of the M+ probe were modified. The center frequency of the S+ probe is well within the range of frequencies used by the predicate device (Aixplorer) for pediatric patients. The system's software was upgraded to accommodate these changes. The new probe uses the same principle of operation, design, materials, manufacturing and testing processes as the primary predicate. Therefore, the new S+ probe does not raise different questions of safety and effectiveness compared to the predicate devices. Bench testing was performed to assure that the device meets its specifications. Measurements of the bias and precision of the device demonstrated substantial equivalence to both predicate devices. {11}------------------------------------------------ A summary of the comparison between the candidate and predicate devices leading to the conclusion that the candidate device raises no new issues of safety or effectiveness is presented in the following table: | | FibroScan® - Pediatric<br>Use | FibroScan® | Aixplorer® | |----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 510(k) # | K150239 | K123806 | K132274 | | Indications for Use | FibroScan® is<br>intended to provide<br>50Hz shear wave<br>speed<br>measurements and<br>estimates of tissue<br>stiffness through<br>internal structures of<br>the body.<br>FibroScan® is<br>indicated for<br>noninvasive<br>measurement of<br>shear wave speed<br>and estimate of<br>stiffness at 50 Hz in<br>the liver. The shear<br>wave speed may be<br>used as an aid to<br>clinical management<br>of pediatric and adult<br>patients with liver<br>disease.<br>Prescription Use<br>Device | FibroScan® is intended<br>to provide 50Hz shear<br>wave speed<br>measurements through<br>internal structures of<br>the body.<br>FibroScan® is indicated<br>for noninvasive<br>measurement of shear<br>wave speed at 50 Hz in<br>the liver. The shear<br>wave speed may be<br>used as an aid to<br>clinical management of<br>patients with liver<br>disease.<br>Prescription Use<br>Device | The SuperSonic<br>Imagine<br>AIXPLORER®)<br>ultrasound system is<br>indicated for use in the<br>following applications:<br>Abdominal, Small<br>Organs,<br>Musculoskeletal,<br>Superficial<br>Musculoskeletal,<br>Vascular, Peripheral<br>Vascular, GYN, Pelvic,<br>Pediatric, Urology,<br>Trans-rectal and Trans-<br>vaginal.<br>The system also<br>provides the ability to<br>measure anatomical<br>structures (Abdominal,<br>Small Organs,<br>Musculoskeletal,<br>Superficial<br>Musculoskeletal,<br>Peripheral Vascular,<br>GYN, Pelvic, Pediatric,<br>Urology, Transrectal<br>and Trans-vaginal). | | Clinical Application | Pediatric | Abdominal | Abdominal<br>Pediatric<br>Other | | Ultrasound Source | Piezoelectric | Piezoelectric | Piezoelectric | | Probe Frequency | Pediatric:<br>5 MHz (S+ Probe) | Adults:<br>3.5 MHz (M+ Probe)<br>2.5 MHz (XL+ Probe) | Pediatric:<br>1 – 6 MHz (SC6-1<br>Probe)<br>4 - 15 MHz (SL15-4<br>Probe) | | Elastography Mode | Vibration-Controlled<br>Transient™ | Vibration-Controlled<br>Transient™ | ShearWave<br>Elastography™ | | Bias | (-13.5%) – (3.6%) | (-13.9%) – (1.3%) | (-7.2%) – (43.4%)2 | | Precision | (0.7%) - (2.0%) | (0%) - (3.1%) | (0%) - (3.4%)3 | 3 Pediatric probes